Qiming Venture Partners Named Top VC Fund in Yangtze River Delta Region by China FOF Research Center
The awards aim to recognize outstanding institutions in the private equity fund-of-funds and fund industries across the Yangtze River Delta region, and to promote the healthy development of the equity investment sector.
Recently, the China FOF Research Center officially released the 2025 Best Investment Institutions in the Yangtze River Delta Region rankings. The awards aim to recognize outstanding private equity fund-of-funds and fund institutions in the region, promoting the healthy development of the equity investment industry.
This year's rankings include lists for Top 30 VC Funds, Top 20 PE Funds, and Top 10 Early-Stage Funds in the Yangtze River Delta for 2025. Qiming Venture Partners ranked #1 on the 2025 Best VC Funds list.
Qiming Venture Partners
Awarded
2025 Best VC Fund in the Yangtze River Delta Region — #1
In the equity investment industry, the Yangtze River Delta is fertile ground for investment. On one hand, numerous technology innovation enterprises continue to emerge; on the other, industrial funds in the region have become highly active under policy encouragement, creating a two-way dynamic between science-driven industries and investment institutions.
Source | China FOF Research Center
Past Highlights
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.